Variability in antifungal utilization among neonatal, pediatric, and adult inpatients in academic medical centers throughout the United States of America

Table 4 Antifungal use among overall patient groups and the adult group by hospital echinocandin restriction

Agent	Overall			Adults
	Restriction: n = 43	No Restriction: n = 17	p-value (t-ratio or Z-statistic)	Restriction: n = 43	No Restriction: n = 17	p-value (t-ratio)
Fluconazole	29.4 (24.5 to 34.3)	28.8 (22.5 to 35)	0.16^a (0.48)	39 (34 to 44.2)	36 (24.2 to 45.2)	0.15^b (0.8)
Echinocandins	10.9 (8 to 14)	8.6 (4.8 to 12.4)	0.34^a (−0.9)	15 (12 to 18.4)	12 (8.5 to 15.7)	0.41^b (1.3)
All Antifungals	53.7 (43.1 to 64.4)	49.7 (35.8 to 63.5)	0.3^a (−0.08)	76 (63.6 to 89)	66 (44 to 88.4)	< 0.001^b (0.83)
Invasive Fungal Infections	0.72 (0.55 to 0.9)	0.65 (0.53 to 0.77)	0.538^b (1.41)	0.81 (0.65 to 0.97)	0.72 (0.57 to 0.86)	0.3934^b (0.57)

Antifungal data presented as mean (95% CI) days of therapy/1000 patient days
Invasive fungal infections data presented as mean (SD) admissions/1000 patient days
^a Wilcoxon rank sum compared hospitals restricting echinocandins to those without restrictions
^b T-test compared hospitals restricting echinocandins to those without restrictions
Bolded p-values were statistically significant

ISSN: 1471-2334